Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial

John C. Wood, Tara Glynos, Alexis Thompson, Patricia Giardina, Paul Harmatz, Barinder P. Kang, Carole Paley, Thomas D. Coates

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


The trial CICL670AUS04 was a single arm, open-label study of the cardiac efficacy of 18 months of deferasirox monotherapy [1]. Cardiac response in this study was related to the degree of liver siderosis. Patients with mild to moderate liver siderosis improved their cardiac T2* while more severely siderotic patients did not, regardless of initial cardiac iron burden. In this letter, we report 2-year data in those patients who completed a 6-month extension phase (N = 10). Cardiac and liver iron improved steadily during the 24-month period, with final cardiac T2* and LIC improving 37% and 27%, respectively, in this cohort. Serum ferritin and LVEF were not statistically different at any time-point. When the extension phase (18-24 months) was considered in isolation, serum ferritin, liver iron concentration, and left ventricular ejection fraction were nearly identical to 18 month results. Despite this, cardiac T2* continued to trend higher, increasing 12.7% from 9.5 ms to 10.7 ms (P = 0.06). Thus defersirox continued to demonstrate cardiac efficacy in patients with mild to moderate hepatic siderosis throughout 2 years of therapy.

Original languageEnglish (US)
Pages (from-to)818-819
Number of pages2
JournalAmerican Journal of Hematology
Issue number10
StatePublished - Oct 2010

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial'. Together they form a unique fingerprint.

Cite this